Literature DB >> 30068667

Projections in Breast and Lung Cancer Mortality among Women: A Bayesian Analysis of 52 Countries Worldwide.

Juan Carlos Martín-Sánchez1, Nuno Lunet2,3, Adrián González-Marrón1, Cristina Lidón-Moyano1, Nuria Matilla-Santander1, Ramon Clèries4,5, Matteo Malvezzi6, Eva Negri7, Samantha Morais2, Ana Rute Costa2, Ana Ferro2, Luisa Lopes-Conceição2, Carlo La Vecchia6, Jose M Martínez-Sánchez8,9.   

Abstract

Among women, lung cancer mortality rates have surpassed those for breast cancer in several countries. This reflects the breast cancer mortality declines due to access to screening and effective treatment alongside the entrance of certain countries in stages of the tobacco epidemic in which smoking becomes more prevalent in women. In this study, we project lung and breast cancer mortality until 2030 in 52 countries. Cancer mortality data were obtained from the WHO Mortality Database. Age-standardized mortality rates (ASMR), per 100,000, were calculated (direct method) for 2008 to 2014 and projected for the years 2015, 2020, 2025, and 2030 using a Bayesian log-linear Poisson model. In 52 countries studied around the world, between 2015 and 2030, the median ASMR are projected to increase for lung cancer, from 11.2 to 16.0, whereas declines are expected for breast cancer, from 16.1 to 14.7. In the same period, the ASMR will decrease in 36 countries for breast cancer and in 15 countries for lung cancer. In half of the countries analyzed, and in nearly three quarters of those classified as high-income countries, the ASMR for lung cancer has already surpassed or will surpass the breast cancer ASMR before 2030. The mortality for lung and breast cancer is higher in high-income countries than in middle-income countries; lung cancer mortality is lower in the latter because the tobacco epidemic is not yet widespread. Due to these observed characteristics of lung cancer, primary prevention should still be a key factor to decrease lung cancer mortality.Significance: The mortality for lung and breast cancer is projected to be higher in high-income countries than in middle-income countries, where lung cancer mortality is expected to surpass breast cancer mortality before 2030. Cancer Res; 78(15); 4436-42. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 30068667     DOI: 10.1158/0008-5472.CAN-18-0187

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Aromatase inhibitors combined with aspirin to prevent lung cancer in preclinical models.

Authors:  Patricia A Young; Richard J Pietras
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 2.  Lung cancer LDCT screening and mortality reduction - evidence, pitfalls and future perspectives.

Authors:  Matthijs Oudkerk; ShiYuan Liu; Marjolein A Heuvelmans; Joan E Walter; John K Field
Journal:  Nat Rev Clin Oncol       Date:  2020-10-12       Impact factor: 66.675

3.  Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study).

Authors:  Mariano Provencio; Enric Carcereny; Delvys Rodríguez-Abreu; Rafael López-Castro; María Guirado; Carlos Camps; Joaquim Bosch-Barrera; Rosario García-Campelo; Ana Laura Ortega-Granados; José Luis González-Larriba; Joaquín Casal-Rubio; Manuel Domine; Bartomeu Massutí; María Ángeles Sala; Reyes Bernabé; Juana Oramas; Elvira Del Barco
Journal:  Transl Lung Cancer Res       Date:  2019-08

4.  A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer.

Authors:  Changyan Feng; Huiqing Yu; Haike Lei; Haoyang Cao; Mengting Chen; Shihong Liu
Journal:  BMC Palliat Care       Date:  2022-05-18       Impact factor: 3.234

5.  Epidemiological and ES cell-based functional evaluation of BRCA2 variants identified in families with breast cancer.

Authors:  Teresa Sullivan; Eswary Thirthagiri; Chan-Eng Chong; Stacey Stauffer; Susan Reid; Eileen Southon; Tiara Hassan; Aravind Ravichandran; Eldarina Wijaya; Joanna Lim; Nur Aishah Mohd Taib; Farhana Fadzli; Cheng Har Yip; Mikael Hartman; Jingmei Li; Rob M van Dam; Susan L North; Ranabir Das; Douglas F Easton; Kajal Biswas; Soo-Hwang Teo; Shyam K Sharan
Journal:  Hum Mutat       Date:  2020-12-31       Impact factor: 4.700

6.  Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.

Authors:  Xiao-Feng Li; Wei-Zhang Shen; Xin Jin; Ping Ren; Jie Zhang
Journal:  Sci Rep       Date:  2020-07-08       Impact factor: 4.379

7.  PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1.

Authors:  Haihong Guo; Fabian Treude; Oliver H Krämer; Bernhard Lüscher; Jörg Hartkamp
Journal:  Sci Rep       Date:  2019-06-19       Impact factor: 4.379

Review 8.  An Overview of Lung Cancer in Women and the Impact of Estrogen in Lung Carcinogenesis and Lung Cancer Treatment.

Authors:  Vianey Rodriguez-Lara; Maria Rosa Avila-Costa
Journal:  Front Med (Lausanne)       Date:  2021-05-17

Review 9.  Epidemiology of lung cancer in China.

Authors:  Maomao Cao; Wanqing Chen
Journal:  Thorac Cancer       Date:  2018-11-28       Impact factor: 3.500

10.  Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis.

Authors:  Hao Tang; Longyu Jin; Zhang Zhang; Zhibin Jiang; Zeeshan Malik
Journal:  Front Oncol       Date:  2021-06-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.